Longeveron Highlights Laromestrocel Data Showing Reduced Brain Neuroinflammation in Mild Alzheimer’s Disease
Longeveron Inc. will present data from its CLEAR MIND study on laromestrocel's effects on brain neuroinflammation in mild Alzheimer's disease at the CTAD 2025 conference. The presentation will occur from December 1-4, 2025, in San Diego, California. The findings have not yet been disclosed.
Longeveron Inc. announced that data from its clinical study evaluating laromestrocel in mild Alzheimer’s disease has been selected for poster presentation at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025), scheduled for December 1-4, 2025, in San Diego, California. The presentation, titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study,” will share findings related to neuroinflammation outcomes following laromestrocel treatment. The results are set to be presented at the conference and have not yet been disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9578538-en) on November 19, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
